ABOS
Acumen Pharmaceuticals Inc

1,319
Mkt Cap
$136.9M
Volume
447,078.00
52W High
$3.60
52W Low
$0.8551
PE Ratio
-1.09
ABOS Fundamentals
Price
$2.19
Prev Close
$2.26
Open
$2.28
50D MA
$2.69
Beta
1.63
Avg. Volume
354,555.27
EPS (Annual)
-$2.00
P/B
1.88
Rev/Employee
$0.00
$42.23
Loading...
Loading...
News
all
press releases
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year?
Here is how Acumen Pharmaceuticals, Inc. (ABOS) and ADC Therapeutics SA (ADCT) have performed compared to their sector so far this year.
Zacks·11h ago
News Placeholder
More News
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised Acumen Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday...
MarketBeat·2d ago
News Placeholder
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the stock, Marketbeat Ratings...
MarketBeat·3d ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) Receives "Buy" Rating from BTIG Research
BTIG Research reissued a "buy" rating and issued a $8.00 target price on shares of Acumen Pharmaceuticals in a report on Thursday...
MarketBeat·4d ago
News Placeholder
Acumen Pharmaceuticals Q4 Earnings Call Highlights
Acumen Pharmaceuticals (NASDAQ:ABOS) outlined progress across its lead Alzheimer's disease program and an emerging "enhanced brain delivery" (EBD) platform during its fourth-quarter and full-year 2025 update, while management reiterated expectations for a key Phase 2 readout later in 2026 and provid...
MarketBeat·4d ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) Announces Earnings Results, Beats Expectations By $0.09 EPS
Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) released its earnings results on Thursday. The company reported ($0.41) earnings per share for the quarter, topping analysts' consensus estimates of ($0.50) by $0.09...
MarketBeat·4d ago
News Placeholder
Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Monday
Acumen Pharmaceuticals (NASDAQ:ABOS) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-acumen-pharmaceuticals-inc-stock...
MarketBeat·8d ago
News Placeholder
Wall Street Zen Downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) to Sell
Wall Street Zen downgraded Acumen Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·10d ago
News Placeholder
Acumen Pharmaceuticals Spotlights Sabirnetug Phase II Progress, JCR Brain-Delivery Partnership at Conference
Acumen Pharmaceuticals (NASDAQ:ABOS) executives outlined key clinical and research milestones for the company's Alzheimer's disease pipeline during a discussion focused on its lead antibody, sabirnetug, and an enhanced brain delivery (EBD) collaboration with Japan-based JCR Pharmaceuticals. Company...
MarketBeat·12d ago
News Placeholder
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $8.00
BTIG Research lifted their price objective on Acumen Pharmaceuticals from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Monday...
MarketBeat·14d ago
<
1
2
...
>

Latest ABOS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.